Terms: = Liver cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
283 results:
1. Predicting effect of anti-PD-1/pd-l1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
2. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
3. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma.
Liu J; Li W; Lu R; Xu J; Jiang C; Duan J; Zhang L; Wang G; Chen J
Oncol Res; 2024; 32(4):717-726. PubMed ID: 38560576
[TBL] [Abstract] [Full Text] [Related]
5. Long non-coding RNAFOXD1-AS1 modulated CTCs epithelial-mesenchymal transition and immune escape in hepatocellular carcinoma in vitro by sponging miR-615-3p.
Guo BL; Zheng QX; Jiang YS; Zhan Y; Huang WJ; Chen ZY
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2050. PubMed ID: 38517478
[TBL] [Abstract] [Full Text] [Related]
6. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
7. Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity.
Wang X; Niu R; Yang H; Lin Y; Hou H; Yang H
Cell Biol Int; 2024 May; 48(5):577-593. PubMed ID: 38501437
[TBL] [Abstract] [Full Text] [Related]
8. New advances in the study of PD-1/pd-l1 inhibitors-induced liver injury.
Yue M; Li C; Li G
Int Immunopharmacol; 2024 Apr; 131():111799. PubMed ID: 38460297
[TBL] [Abstract] [Full Text] [Related]
9. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
[TBL] [Abstract] [Full Text] [Related]
10. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to pd-l1 monoclonal antibody therapy.
Wang H; Zhou Q; Xie DF; Xu Q; Yang T; Wang W
Cell Death Dis; 2024 Feb; 15(2):165. PubMed ID: 38388484
[TBL] [Abstract] [Full Text] [Related]
11. Interferon-α induces differentiation of cancer stem cells and immunosuppression in hepatocellular carcinoma by upregulating CXCL8 secretion.
Ma YT; Zheng L; Zhao CW; Zhang Y; Xu XW; Wang XY; Niu GP; Man ZS; Gu F; Chen YQ
Cytokine; 2024 May; 177():156555. PubMed ID: 38387232
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract] [Full Text] [Related]
13. Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures.
Ahn B; Ahn HS; Shin J; Jun E; Koh EY; Ryu YM; Kim SY; Sung CO; Shim JH; Hong J; Kim K; Kang HJ
Liver Int; 2024 May; 44(5):1202-1218. PubMed ID: 38363048
[TBL] [Abstract] [Full Text] [Related]
14. Treatment and prognostic implications of strong pd-l1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
15. Tumor cell-derived LC3B
Chen YQ; Man ZS; Zheng L; Zhang Y; Zhao CW; Ma YT; Zhou J; Wang P; Yu Y; Gu F; Niu GP
Clin Immunol; 2024 Apr; 261():109925. PubMed ID: 38310993
[TBL] [Abstract] [Full Text] [Related]
16. Frequent expression of pd-l1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract] [Full Text] [Related]
17. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
18. DEAD-box helicase 1 inhibited CD8
Liu J; Yang T; Luo Y; Ma Z; Yu Z; Zhang L; Liu G; Wen J; Lu G; Zhang G; Zhao Y; Luo W; Li Y; Yang N; Zhou J; Lu Y; Chen S; Zeng X
Cancer Sci; 2024 Mar; 115(3):763-776. PubMed ID: 38243657
[TBL] [Abstract] [Full Text] [Related]
19. Role of stromal pd-l1 expression in colorectal liver metastasis.
Takasu C; Morine Y; Yoshikawa K; Nakao T; Tokunaga T; Nishi M; Kashihara H; Wada Y; Yoshimoto T; Shimada M
BMC Cancer; 2024 Jan; 24(1):97. PubMed ID: 38233811
[TBL] [Abstract] [Full Text] [Related]
20. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
[Next]